Answers are grounded in this paper and cite their sources.
A substantial share of older persons with life-limiting diseases receive drugs of questionable clinical benefit during their last months of life. Adequate training, guidance and resources are needed to rationalize and deprescribe drug treatments for older adults near the end of life.
No takes yet. Share an insight, caveat, or question.
Morin et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: